Title : R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms.

Pub. Date : 2020 Dec 8

PMID : 33323828






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory disease and had poor survival outcomes. Doxorubicin DNA damage inducible transcript 3 Homo sapiens